Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Novartis AG ADS (NY: NVS)
74.15 USD  -0.86 (-1.15%)
Official Closing Price  /  Updated: 6:40 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
Blog posts about Novartis AG ADS
 
< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
(GILD) Gilead Sciences Shows Uptrend in Earnings Estimates
March 05, 2010
Earnings estimates for Gilead Sciences (GILD) are on the rise following the release of strong fourth quarter and full year 2009 results. The company’s earnings per share (EPS) came in at 90 cents, well... Read More
category NVS , Glaxosmithkline plc , Biotechnology , and 5 more.
from Stock Blog Hub
Uptrend In Gilead’s Estimates
March 05, 2010
Earnings estimates for Gilead Sciences (NASDAQ:GILD) are on the rise following the release of strong fourth quarter and full year 2009 results. The company’s earnings per share (EPS) came in at 90... Read More
category External Research , Contributor , GILD , and 6 more.
from DailyMarkets.com
(BMY) Bristol-Myers Squibb Gets Good News From the FDA
March 03, 2010
Recently, Bristol-Myers Squibb Co. (BMY) announced that the advisory committee of the U.S. Food and Drug Administration (FDA) recommended approval for belatacept, the company’s candidate for treating... Read More
category NVS , Healthcare , Drug Manufacturers / Major , and 5 more.
from Stock Blog Hub
(ACL) Alcon – Solid Growth Across All Segments – Novartis Wants to Acquire Alcon
March 03, 2010
Alcon (ACL) is delivering solid growth across all business segments and pays a dividend yield of 2.3%. Company Description Alcon is one of the world’s leading suppliers of eye care products. The... Read More
category AZN , NBY , Glaxosmithkline plc , and 8 more.
from Stock Blog Hub
(HGSI) Human Genome Sciences Reports Lower Fourth Quarter Loss
March 03, 2010
Human Genome Sciences, Inc. (HGSI) reported fourth quarter 2009 net loss of $9.7 million or 6 cents per share, narrower than the Zacks Consensus Estimate of 9 cents and the year-ago loss of $61.9... Read More
category NVS , Glaxosmithkline plc , Biotechnology , and 5 more.
from Stock Blog Hub
Lower Q4 Loss For Human Genome
March 03, 2010
Human Genome Sciences, Inc. (NASDAQ:HGSI) reported fourth quarter 2009 net loss of $9.7 million or 6 cents per share, narrower than the Zacks Consensus Estimate of 9 cents and the year-ago loss of... Read More
category External Research , Contributor , NVS , and 6 more.
from DailyMarkets.com
Good News For Bristol-Myers
March 02, 2010
Recently, Bristol-Myers Squibb Co. (NYSE:BMY) announced that the advisory committee of the U.S. Food and Drug Administration (FDA) recommended approval for belatacept, the company’s candidate for... Read More
category NVS , USA , Stocks , and 5 more.
from DailyMarkets.com
Narrower Q4 Loss For Alnylam
February 26, 2010
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reported a fourth-quarter net loss of 19 cents per share, better than the Zacks Consensus Estimate of a loss of 30 cents and the year-ago loss of 23 cents.  ... Read More
category External Research , Contributor , NVS , and 5 more.
from DailyMarkets.com
(HGSI) Human Genome Sciences Pipeline Bigger than Earnings
February 25, 2010
Human Genome Sciences, Inc. (HGSI) is expected to report fourth quarter as well as fiscal 2009 results shortly. We expect that the company will report a loss of 10 cents per share for the fourth... Read More
category NVS , Glaxosmithkline plc , Biotechnology , and 7 more.
from Stock Blog Hub
(AMGN) Amgen Earns Positive Results From Phase III Drug Study
February 09, 2010
Amgen Inc. (AMGN) received a boost recently when the company announced positive results from a pivotal head-to-head phase III study that was conducted with Amgen’s main pipeline candidate, denosumab.... Read More
category NVS , Amgen Inc , Biotechnology , and 3 more.
from Stock Blog Hub
Positive Results On Amgen Drug « Zacks Investment Research »
February 09, 2010
Amgen Inc. (AMGN) received a boost recently when the company announced positive results from a pivotal head-to-head phase III study that was conducted with Amgen’s main pipeline candidate, denosumab.... Read More
category NVS , USA , AMGN , and 4 more.
from DailyMarkets.com
(GSK) GlaxoSmithKline’s Tykerb Received Accelerated Approval From The U.S. Food and Drug Administration
February 01, 2010
GlaxoSmithKline (GSK) recently announced that it has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the use of Tykerb (lapatinib) as a first-line treatment for women... Read More
category NVS , Glaxosmithkline plc , Healthcare , and 3 more.
from Stock Blog Hub
The States of the Union & Global Economy
January 26, 2010
from Wall Street Greek
(NVS) Novartis AG’s MS Therapy Advances
January 23, 2010
Novartis AG (NVS) recently published full results on its oral multiple sclerosis (MS) therapy FTY720 (fingolimod) in the New England Journal of Medicine. These results were from two pivotal phase III... Read More
category MS , Morgan Stanley , TEVA , and 9 more.
from Stock Blog Hub
Novartis’ MS Therapy Advances
January 22, 2010
Novartis AG (NVS) recently published full results on its oral multiple sclerosis (MS) therapy FTY720 (fingolimod) in the New England Journal of Medicine. These results were from two pivotal phase III... Read More
category UK , TEVA , External Research , and 7 more.
from DailyMarkets.com
Top 10 Hot stocks to buy right now in 2010!
January 22, 2010
Exelon (EXC, news: 48.05 0.00%)- Exelon Corporation is one of the nation’s largest electric utilities with approximately $19 billion in annual revenues. We distribute electricity to approximately 5.4... Read More
category TMO , Sysco , PAYX , and 22 more.
from CEOWORLD Magazine
(ACL) Novartis’ Purchase Offer Inadequate for Alcon
January 21, 2010
Eye care company Alcon, Inc. (ACL) announced that its Independent Director Committee recently responded to Novartis AG’s (NVS) proposal to acquire its minority publicly traded shares. The Committee... Read More
category NVS , ACL , Alcon Inc , and 2 more.
from Stock Blog Hub
Novartis Offer Inadequate For Alcon
January 21, 2010
Eye care company Alcon, Inc. (ACL) announced that its Independent Director Committee recently responded to Novartis AG’s (NVS) proposal to acquire its minority publicly traded shares. The Committee... Read More
category NVS , ACL , Stocks , and 3 more.
from DailyMarkets.com
(NVS) Novartis Collaborates with GenVec on Hearing Loss Treatments
January 20, 2010
Recently, Novartis (NVS) entered into a collaboration with GenVec (GNVC) for the development of treatments for hearing loss and balance disorders. Earlier, preclinical results have found strong... Read More
category GNVC , Novartis AG , NVS , and 7 more.
from Stock Blog Hub
(ACL) What Nestle Wants Nestle Gets – And Right Now, Nestle Wants a Bigger Slice of the Pie
January 18, 2010
by Tony Daltorio, Investment U Research Monday, January 18, 2010 It would take far too long to list the leading brands Nestle ADR (OTC: NSRGY) owns, considering that it’s the world’s biggest food... Read More
category Cadbury plc , KFT , Novartis AG , and 6 more.
from Stock Blog Hub
What Nestle Wants, Nestle Gets… And Right Now, Nestle Wants A Bigger Slice Of The Pie
January 18, 2010
It would take far too long to list the leading brands Nestle ADR (OTC: NSRGY) owns, considering that it’s the world’s biggest food corporation with operations in almost every country. Suffice it to say... Read More
category kft , External Research , Contributor , and 7 more.
from DailyMarkets.com
(ALNY) Alnylam Pharmaceuticals Offers Financial Guidance For 2010
January 14, 2010
Alnylam Pharmaceuticals, Inc. (ALNY) recently provided an update on its key pipeline, scientific and business goals for the next 12 to 18 months coupled with financial guidance for 2010. Alnylam, which... Read More
category Biotechnology , CF Industries Holdings , Alnylam Pharmaceuticals Inc , and 7 more.
from Stock Blog Hub
(HGSI) Human Genome Sciences to Seek Drug Approval in Second Quarter
January 14, 2010
Human Genome Sciences Inc. (HGSI) announced recently that it intends to seek approval for its potential blockbuster lupus drug candidate Benlysta during the second quarter of 2010 in the United States... Read More
category NVS , Glaxosmithkline plc , Biotechnology , and 7 more.
from Stock Blog Hub
HGSI To Seek Drug Approval In 2Q
January 14, 2010
Human Genome Sciences Inc. (HGSI) announced recently that it intends to seek approval for its potential blockbuster lupus drug candidate Benlysta during the second quarter of 2010 in the United States... Read More
category External Research , Contributor , NVS , and 6 more.
from DailyMarkets.com
Alnylam Pharma Guides
January 14, 2010
Alnylam Pharmaceuticals, Inc. (ALNY) recently provided an update on its key pipeline, scientific and business goals for the next 12 to 18 months coupled with financial guidance for 2010.  Alnylam,... Read More
category NVS , ALNY , Stocks , and 4 more.
from DailyMarkets.com
(PFE) Novartis Sees Profits In Alcon – Why You Should Too
January 13, 2010
Tony Daltorio, Investment U Research Tuesday, January 12, 2010 Back in October, I wrote about how pharmaceutical companies captured the financial world’s attention with a myriad of lucrative mergers... Read More
category JNJ , Johnson & Johnson , Novartis AG , and 7 more.
from Stock Blog Hub
(NVS) Novartis Launched Fanapt Into Competitive Schizophrenia Market
January 12, 2010
Recently, Novartis (NVS) launched Fanapt (iloperidone) in the U.S. Its twice daily tablets are for the treatment of schizophrenia in adults. Fanapt received approval from the US Food and Drug... Read More
category Vanda Pharmaceuticals Inc , VNDA , Novartis AG , and 5 more.
from Stock Blog Hub
Novartis Sees Profits In Alcon… Why You Should Too
January 12, 2010
Back in October, I wrote about how pharmaceutical companies captured the financial world’s attention with a myriad of lucrative mergers and acquisitions last year. Some of the more memorable deals... Read More
category External Research , Contributor , ACL , and 5 more.
from DailyMarkets.com
Competitive Schizophrenia Market
January 12, 2010
Recently, Novartis (NVS) launched Fanapt (iloperidone) in the U.S. Its twice daily tablets are for the treatment of schizophrenia in adults. Fanapt received approval from the US Food and Drug... Read More
category VNDA , External Research , Contributor , and 6 more.
from DailyMarkets.com
(MRK) Roche Eyes COPD Market
January 11, 2010
Roche (RHHBY.PK) has entered into an alliance with the Belgian biotech company Galapagos to develop new therapies for the treatment of chronic obstructive pulmonary disease (COPD). While Galapagos will... Read More
category Glaxosmithkline plc , FRX , Novartis AG , and 9 more.
from Stock Blog Hub
< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here